Dr. Tobias Leibfritz

Some interesting ranking but not overly surprised by the general finding - especially around social media. Whilst the fall in Twitter is totally understandable (thank you Elon) it is still amazing to see such low utilisation of one of the top communication channels. Despite regulatory constraints there is still a huge amount of value pharma could add and gain from being more active on social media. And if you want to be truly patient centric then you really do have to be more active on the channel patients are using! #pharma #socialmedia

5

Health is fundamental to everything. Our Head Global Access Michael Oberreiter inspired me, our colleagues in Roche in Austria and key stakeholders in the Austrian healthcare system with his visionary thinking. Too often we discuss healthcare as a cost. But every Euro invested in health has a significant return to society, socio-economic studies prove. Healthy citizens can go to work, pay taxes and care for their loved ones. Let’s get the national stakeholders together to shape health strategies for Austria. Austrian citizens rightfully expect that we care for their health according to highest scientific standards. That does not only mean rapid access to innovative treatments, it also means a lot more prevention. Let’s discuss value. Let’s talk to each other rather than about each other and shape a sustainable healthcare strategy for Austria. Thank you for your visit Michael Oberreiter , you sparked a flame! #healthcare #innovation #healthcarestrategy #systemshaping #prevention #societalvalue #strongertogether #leadership

138

5 Kommentare

📣🎉 I am thrilled to announce Jochen Hurlebaus as our new Chief Strategy Officer and VP Client Partnerships for the 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐚𝐧𝐝 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐰𝐢𝐭𝐡 𝐦𝐮𝐥𝐭𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐬 of our meta-platform for patients and pharma! 🙌 Jochen (many already know him) was previously 𝐇𝐞𝐚𝐝 𝐨𝐟 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 at Roche Diagnostics International and has more than 20 years of combined 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞. ✅ He was responsible for the creation and growth of the STARTUP CREASPHERE powered by Plug and Play, a global innovation program at Roche that has enabled successful co-creation projects with nearly 100 digital health startups worldwide. In the process, Jochen and his team have seen and evaluated more than a 𝐭𝐡𝐨𝐮𝐬𝐚𝐧𝐝 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞. 🥳 We are all the more delighted that Jochen has decided to use all his #knowledge, #energy and #dedication to advance XO Life and the international expansion of the #ImpactMonitor platform in Europe and beyond!   🤩 He believes in the vision of many others: We need a sensible (social) media alternative to Dr. Google, Facebook, Insta, Tik Tok and Co. for all people who take medication, health-related products and are on different therapies. Such groups of 𝐩𝐞𝐨𝐩𝐥𝐞 𝐚𝐫𝐞 𝐯𝐮𝐥𝐧𝐞𝐫𝐚𝐛𝐥𝐞 𝐚𝐧𝐝 𝐧𝐞𝐞𝐝 𝐚 𝐩𝐫𝐨𝐭𝐞𝐜𝐭𝐞𝐝 𝐲𝐞𝐭 𝐞𝐧𝐠𝐚𝐠𝐢𝐧𝐠 𝐬𝐨𝐜𝐢𝐚𝐥 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭. This may be best achieved by a meta-platform rather than dozens of individual apps for many different reasons. 💌 If you would like to find out more, please get in touch with Jochen Hurlebaus or me! 😎 More news to come, stay tuned! #digitalhealthinnovation #patientempowerment #patientengagement #impactmonitorplatform #chiefstrategyofficer #realworlddata #frombigcorporatetosmallstartup

249

20 Kommentare

➡️➡️ Interested in #socialmedia in the #oncology space? Check out our #ESMO24 report! http://dlvr.it/TGNXhL 📥 . 🚀 Our team monitored and analyzed ESMO-related posts on X (previously #Twitter) before, during, and after the event, and here are some key takeaways: 🔍 Key hashtags: Online conversations spotlighted #LCSM, #BCSM, #breastcancer, and #prostatecancer, with notable attention on education-related hashtags. Top Discussion Themes: #Efficacy dominated discussions at 21% 📊, followed by #Data and #clinicaltrials/#studies, both at ~16% 🔬. Leading Voices: #Physicians dominated the conversation at 87% 🎤, followed by #researchers at 7% 🔬. Audience Sentiment: Overwhelmingly positive! 😄 Two-thirds of posts celebrated research breakthroughs & networking opportunities. Text Analytics: #ESMO2024 heavily focused on #lungcancer and #breastcancer, with much discussion around #chemotherapy and #immunotherapy (#pembrolizumab!). 👉 Interested in #socialmedia coverage during conferences? We cover multiple #therapyareas and events! Send us a message at [email protected]! Abbott AbbVie Accord Healthcare Amgen Astellas Pharma AstraZeneca Bayer BeiGene Bicycle Therapeutics BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Caris Life Sciences Daiichi Sankyo Europe GmbH Dr. Reddy's Laboratories Eisai US Eisai EMEA Eli Lilly and Company Exelixis Gilead Sciences GSK Ipsen Jazz Pharmaceuticals Johnson & Johnson Massive Bio MENARINI Group Merck Group EMD Serono, Inc. Moderna MSD Novartis Novocure Owkin PathAI Pfizer Regeneron Roche Sanofi Servier Pharmaceuticals Takeda Oncology #HealthcareConsulting #ESMO2024 #SocialListening #DigitalHealth #MedicalEducation #LucidQuest #CompetitiveMarketing

1

➡️➡️ Interested in #socialmedia in the #oncology space? Check out our #ESMO24 report! http://dlvr.it/TFv55h 📥 . 🚀 Our team monitored and analyzed ESMO-related posts on X (previously #Twitter) before, during, and after the event, and here are some key takeaways: 🔍 Key hashtags: Online conversations spotlighted #LCSM, #BCSM, #breastcancer, and #prostatecancer, with notable attention on education-related hashtags. Top Discussion Themes: #Efficacy dominated discussions at 21% 📊, followed by #Data and #clinicaltrials/#studies, both at ~16% 🔬. Leading Voices: #Physicians dominated the conversation at 87% 🎤, followed by #researchers at 7% 🔬. Audience Sentiment: Overwhelmingly positive! 😄 Two-thirds of posts celebrated research breakthroughs & networking opportunities. Text Analytics: #ESMO2024 heavily focused on #lungcancer and #breastcancer, with much discussion around #chemotherapy and #immunotherapy (#pembrolizumab!). 👉 Interested in #socialmedia coverage during conferences? We cover multiple #therapyareas and events! Send us a message at [email protected]! Abbott AbbVie Accord Healthcare Amgen Astellas Pharma AstraZeneca Bayer BeiGene Bicycle Therapeutics BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Caris Life Sciences Daiichi Sankyo Europe GmbH Dr. Reddy's Laboratories Eisai US Eisai EMEA Eli Lilly and Company Exelixis Gilead Sciences GSK Ipsen Jazz Pharmaceuticals Johnson & Johnson Massive Bio MENARINI Group Merck Group EMD Serono, Inc. Moderna MSD Novartis Novocure Owkin PathAI Pfizer Regeneron Roche Sanofi Servier Pharmaceuticals Takeda Oncology #HealthcareConsulting #ESMO2024 #SocialListening #DigitalHealth #MedicalEducation #LucidQuest #CompetitiveMarketing

2

Developing drugs is risky, expensive and difficult. Doing that for rare diseases even more. Check out the great article about our passion at AOP Health to still go for this #research and #development

42

Biosimilar medicines, and the competition they create, are vital for expanding access to biologics and improving healthcare sustainability.   However, many key biologics set to lose exclusivity in the next decade do not have a biosimilar candidate in the pipeline.    This failure to attract biosimilar competition, also called the ‘biosimilar void’, is a stark reminder that we must continue to address the challenges threatening biosimilar market sustainability or face damaging repercussions on our already-stretched healthcare systems.    In my opinion piece with the European Pharmaceutical Review, I dig deeper into what a biosimilar void could mean for patients and healthcare systems in Europe. I also discuss how regulators, government bodies, payors and the industry must collaborate to create a sustainable European market that promotes more biosimilar competition. This will allow biosimilars to do what they are supposed to do; increase access, drive sustainability and foster innovation.     You can read my thoughts in full in EPR's latest Pharma Horizons report through the link below.👇 https://lnkd.in/eX-aqeJf   Thanks, EPR, for the chance to discuss this important topic!   Sandoz #Sandoz #Healthcare #PatientAccess

125

➡️➡️ Interested in #socialmedia in the #oncology space? Check out our #ESMO24 report! http://dlvr.it/TGDcbk 📥 . 🚀 Our team monitored and analyzed ESMO-related posts on X (previously #Twitter) before, during, and after the event, and here are some key takeaways: 🔍 Key hashtags: Online conversations spotlighted #LCSM, #BCSM, #breastcancer, and #prostatecancer, with notable attention on education-related hashtags. Top Discussion Themes: #Efficacy dominated discussions at 21% 📊, followed by #Data and #clinicaltrials/#studies, both at ~16% 🔬. Leading Voices: #Physicians dominated the conversation at 87% 🎤, followed by #researchers at 7% 🔬. Audience Sentiment: Overwhelmingly positive! 😄 Two-thirds of posts celebrated research breakthroughs & networking opportunities. Text Analytics: #ESMO2024 heavily focused on #lungcancer and #breastcancer, with much discussion around #chemotherapy and #immunotherapy (#pembrolizumab!). 👉 Interested in #socialmedia coverage during conferences? We cover multiple #therapyareas and events! Send us a message at [email protected]! Abbott AbbVie Accord Healthcare Amgen Astellas Pharma AstraZeneca Bayer BeiGene Bicycle Therapeutics BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Caris Life Sciences Daiichi Sankyo Europe GmbH Dr. Reddy's Laboratories Eisai US Eisai EMEA Eli Lilly and Company Exelixis Gilead Sciences GSK Ipsen Jazz Pharmaceuticals Johnson & Johnson Massive Bio MENARINI Group Merck Group EMD Serono, Inc. Moderna MSD Novartis Novocure Owkin PathAI Pfizer Regeneron Roche Sanofi Servier Pharmaceuticals Takeda Oncology #HealthcareConsulting #ESMO2024 #SocialListening #DigitalHealth #MedicalEducation #LucidQuest #CompetitiveMarketing

1

How are recent policies adopted by the German government viewed by the country’s largest pharmaceutical company? And what further changes does it consider necessary? Dr Fridtjof Traulsen, CEO of Boehringer Ingelheim Deutschland GmbH, expressed his views in a recent interview (tinyurl.com/mjrtd9m8). Measures in the Medical Research Act (MFG) to facilitate clinical trials in Germany are a positive development. Traulsen said: “What we also very much welcome is the linking of the so-called AMNOG guardrails to the research activities of a company in Germany.” The guardrails for rebate negotiation for medicines that have patent-protected comparators and are judged to offer minor, unquantifiable or no additional benefit will be waived if at least 5% of patients in clinical trials were treated at the drug developer’s expense in German test centres. (Guardrails will still apply if the appropriate comparator therapy is a generic.) (tinyurl.com/2nnha3sd) However, Traulsen thinks “the time limit stipulated in the law is inappropriate and counterproductive: after 30 months there will be an evaluation of the company's general research activities in Germany—not linked to the respective product. This is intended to give the Statutory Health Insurance system (GKV) the opportunity to renegotiate the drug’s reimbursement amount. This creates bureaucracy and frustrates the purpose of the regulation.” Traulsen also believes the AMNOG procedure needs to be reformed: “It is not always possible to carry out classic randomised clinical trials with an appropriate comparator therapy, particularly in the area of novel therapies and for serious or rare diseases. More flexibility is needed in the benefit assessment procedure so that alternative scientific evidence can also be taken into account. This is the only way to strengthen the development of innovative medicines in Germany in the long term.” He sounded a warning to the government: “If—as in 2022 with the Statutory Health Insurance Finance Stabilisation Act—our contribution to innovation and the economy is no longer recognised and the pharmaceutical industry is instead reduced to a cost factor in the healthcare system, then it will be an increasing challenge to bring innovation and investment to Germany. If AMNOG reform does not materialise, it will be difficult even for us in the long term because patients in Germany will benefit from innovative therapies much later or not at all, making Germany unattractive as a location for clinical research and as a market.” In his view, laws that have been passed, such as the MFG, must be implemented quickly. He hopes to see a reduction in the approval times for clinical trials within a year—from the current average in Germany of 120 days to closer to the Spanish average of 60 days: “We need to become competitive again.” #Germany #AMNOG #reform #innovation #rebates

37

How much does a digital transformation 🤖 costs 💰 at a major Pharma 💊 ? (Response: A LOT 😱 ) I often wondered 🤔 and now I know💡: 2,2Bn CHF (=$2,3Bn) ... that's the figure that Roche communicated during their digital transformation days. The presentation is quite long (>2h), but it's jam packed with great information. For anyone working at the interface between Pharma / Data & Tech it's a must watch 😳 Link in the comment section below 👇

10

2 Kommentare

🚀 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗲 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝗱𝗲𝗿𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺! - 𝗔 𝗪𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿 𝗳𝗼𝗿 𝗣𝗵𝗮𝗿𝗺𝗮 𝗠𝗮𝗻𝗮𝗴𝗲𝗿𝘀. The new whitepaper by Healthcare Manufaktur offers deep insights into the challenges and opportunities for pharma managers in the digital age. Learn about: ✅ How to switch from traditional to ecosystem-centered marketing and sales approaches and successfully navigate access barriers ✅ Why "helicopter specialists" are already relevant hidden champions today and why you can't find the point of decision using conventional methods ✅ How AI and knowledge graphs revolutionize your decision-making ✅ Strategies for effective navigation in multi-stakeholder environments The two authors show how you can master the market's complexity with innovative technologies and data analysis, positioning your company as an indispensable partner in healthcare. Are you ready to take your strategies to the next level? Get inspired! 💡🧠 #PharmaMarketing #Sales2PunktNull #EcosystemManagement #Access #DigitaleTransformation #HealthcareEcosystem #AI #Innovation Who wants to learn more about the tools and outcomes, use cases, and success stories? 📣 Comment or share the post! 🙏

1

➡️➡️ Interested in #socialmedia in the #oncology space? Check out our #ESMO24 report! http://dlvr.it/TG48BL 📥 . 🚀 Our team monitored and analyzed ESMO-related posts on X (previously #Twitter) before, during, and after the event, and here are some key takeaways: 🔍 Key hashtags: Online conversations spotlighted #LCSM, #BCSM, #breastcancer, and #prostatecancer, with notable attention on education-related hashtags. Top Discussion Themes: #Efficacy dominated discussions at 21% 📊, followed by #Data and #clinicaltrials/#studies, both at ~16% 🔬. Leading Voices: #Physicians dominated the conversation at 87% 🎤, followed by #researchers at 7% 🔬. Audience Sentiment: Overwhelmingly positive! 😄 Two-thirds of posts celebrated research breakthroughs & networking opportunities. Text Analytics: #ESMO2024 heavily focused on #lungcancer and #breastcancer, with much discussion around #chemotherapy and #immunotherapy (#pembrolizumab!). 👉 Interested in #socialmedia coverage during conferences? We cover multiple #therapyareas and events! Send us a message at [email protected]! Abbott AbbVie Accord Healthcare Amgen Astellas Pharma AstraZeneca Bayer BeiGene Bicycle Therapeutics BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Caris Life Sciences Daiichi Sankyo Europe GmbH Dr. Reddy's Laboratories Eisai US Eisai EMEA Eli Lilly and Company Exelixis Gilead Sciences GSK Ipsen Jazz Pharmaceuticals Johnson & Johnson Massive Bio MENARINI Group Merck Group EMD Serono, Inc. Moderna MSD Novartis Novocure Owkin PathAI Pfizer Regeneron Roche Sanofi Servier Pharmaceuticals Takeda Oncology #HealthcareConsulting #ESMO2024 #SocialListening #DigitalHealth #MedicalEducation #LucidQuest #CompetitiveMarketing

2

5QQ to... Five Quick Questions to Stefan Walzer: Revolutionizing Healthcare Market Access with AI In this interview, Stefan Walzer, CEO of MArS Market Access & Pricing Strategy GmbH, reveals how AI-driven projects like Q-BO and mAxInsights are transforming healthcare. He shares challenges, strategic insights, and advice for aspiring leaders. Discover the future of healthcare with AI! #HealthcareInnovation #AI #MarketAccess #Leadership #FutureOfHealthcare #Interview

2

1 Kommentar

5QQ to... Five Quick Questions to Stefan Walzer: Revolutionizing Healthcare Market Access with AI In this interview, Stefan Walzer, CEO of MArS Market Access & Pricing Strategy GmbH, reveals how AI-driven projects like Q-BO and mAxInsights are transforming healthcare. He shares challenges, strategic insights, and advice for aspiring leaders. Discover the future of healthcare with AI! #HealthcareInnovation #AI #MarketAccess #Leadership #FutureOfHealthcare #Interview

1

1 Kommentar

The role and use of RWE has evolved and broadened rapidly over the last few years. ⏳ Prof. Dr. Thomas Wilke, from our "Generating RWE for Optimising Market/Patient Access" course, has made a handy overview of the potential use of RWE along the entire product lifecycle. 📊 ❓ Would you like to receive this infographic? 💬 Like this post & write YES in the comments and I’ll send it to you! -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me  #pharma #realworldevidence #realworlddata #realworldstrategy GIPAM

12

20 Kommentare

5QQ to... Five Quick Questions to Stefan Walzer: Revolutionizing Healthcare Market Access with AI In this interview, Stefan Walzer, CEO of MArS Market Access & Pricing Strategy GmbH, reveals how AI-driven projects like Q-BO and mAxInsights are transforming healthcare. He shares challenges, strategic insights, and advice for aspiring leaders. Discover the future of healthcare with AI! #HealthcareInnovation #AI #MarketAccess #Leadership #FutureOfHealthcare #Interview

1

1 Kommentar